Phaseline

Targets › DLL3

DLL3 (Delta-like protein 3): drug programs, companies and trials

18 programs from 15 companies in 63 trials: 33 Phase 1, 19 Phase 2, 11 Phase 3; Oncology; next expected readout Nov 2026.

Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. (UniProt, Q9NYJ7)

Open in Phaseline: the race on DLL3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Daiichi SankyoIfinatamab deruxtecan (DS-7300a, I-DXd)
Anti-B7H3 antibody-drug conjugate
B7H3, DLL3Phase 3Small Cell Lung Cancer; Esophageal Squamous Cell Carcinoma; Extensive-stage Small-cell Lung Cancer; Advanced Solid Tumor …Dec 2026
Boehringer IngelheimObrixtamig
DLL3-targeting antibody-drug conjugate
DLL3Phase 3Small Cell Lung Cancer (SCLC); Extrapulmonary Neuroendocrine Cancer (epNEC); Small Cell Lung Carcinoma (SCLC); Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 …Mar 2027
AmgenTarlatamab
T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent
CD3E, CD3G, CD3D, DLL3Phase 3Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Small-cell Lung Cancer; Extensive-Stage Small-Cell Lung Cancer …Apr 2027
AbbVieABBV-706
Delta-like ligand 3 (DLL3) targeted therapy
DLL3Phase 3Small Cell Lung Cancer; Advanced Solid TumorsNov 2027
Boehringer IngelheimBI 764532
DLL3-targeting antibody-drug conjugate
DLL3Phase 2Small Cell Lung Carcinoma; Small Cell Lung Carcinoma (SCLC); Glioma; Neuroendocrine NeoplasmsDec 2026
Tingting Yuan[⁶⁸Ga]Ga-PFD3
DLL3-targeting PET tracer; nanobody conjugate with ⁶⁸Ga radiolabel
DLL3Phase 2Neuroendocrine TumorsDec 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesGC511B CAR-T Cell Injection
Anti-DLL3 CAR-T cell therapy
DLL3Phase 1Relapsed/Refractory Small Cell Lung CancerNov 2026
Sichuan Universityα-PD-L1/4-1BB DLL3 CAR-T (BHP01)
dual-targeted CAR-T cell therapy targeting PD-L1 and DLL3 with 4-1BB costimulatory domain
CD274, DLL3Phase 1Small Cell Lung Cancer Extensive StageDec 2026
Abdera Therapeutics225Ac-ABD147
DLL3-targeting antibody fragment conjugated with actinium-225
DLL3Phase 1Small-Cell Lung Cancer (SCLC)Jan 2027
Beijing BiotechEB-DART-NK01
Allogeneic dual-target CAR-NK cells (DLL3/CD56, DLL3/GD2, or CD56/GD2)
DLL3, CD56, GD2Phase 1Small Cell Lung Cancer (SCLC)Feb 2027
Phanes TherapeuticsPeluntamig (PT217)
Bispecific antibody against DLL3 and CD47
DLL3, CD47Phase 1Small Cell Lung Cancer (SCLC)Dec 2027
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Gocatamig (HPN328, MK-6070)
DLL3-targeted trispecific antibody
DLL3Phase 1Small-Cell Lung CancerJan 2028
Molecular Partners[212Pb]Pb-MP0712
DLL3-targeting radioligand therapy (alpha particle emitter)
DLL3Phase 1Large Cell Neuroendocrine CarcinomaSep 2028
IDEAYA BiosciencesIDE849
DLL3-targeted bispecific antibody
DLL3Phase 1Small-cell Lung CancerJul 2029
Memorial Sloan Kettering Cancer CenterDLL3-SAVVYZ-IL18 CAR T cell
DLL3-targeting CAR T cell with IL-18 enhancement
DLL3Phase 1Neuroendocrine CancerAug 2029
NovartisDJI136
DLL3-targeted CAR-T therapy
DLL3Phase 1Extensive-stage Small Cell Lung Cancer (ES-SCLC)Mar 2031
Novartis[111In]In-ETN029
Indium-111 labeled imaging agent targeting DLL3
DLL3Phase 1Small Cell Lung CarcinomaAug 2031
Novartis[225Ac]Ac-ETN029
Alpha-emitting radioligand targeting DLL3
DLL3Phase 1Small Cell Lung CarcinomaAug 2031

Conditions

Small Cell Lung Cancer (7) Small Cell Lung Cancer (SCLC) (6) Extensive Stage Small Cell Lung Cancer (4) Small Cell Lung Carcinoma (4) Small Cell Lung Carcinoma (SCLC) (4) Small-cell Lung Cancer (3) Relapsed/Refractory Small Cell Lung Cancer (2) Glioma (2) Esophageal Squamous Cell Carcinoma (1) Extensive-stage Small-cell Lung Cancer (1) Advanced Solid Tumor (1) Extensive Stage-small Cell Lung Cancer (1)

Modalities

small molecule (6), mixed (5), antibody (3), other (3), protein or peptide (1)

Companies

Novartis (3) Boehringer Ingelheim (2) Daiichi Sankyo (1) Amgen (1) Molecular Partners (1) AbbVie (1) IDEAYA Biosciences (1) Beijing Biotech (1) Phanes Therapeutics (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) Memorial Sloan Kettering Cancer Center (1) Sichuan University (1) Abdera Therapeutics (1) Tingting Yuan (1) Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)

Related targets

B7H3 (1) CD3E (1) CD3G (1) CD3D (1) CD56 (1) GD2 (1) CD47 (1) CD274 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.